Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Johnson & Johnson's Rybrevant (amivantamab) wins FDA accelerated approval for recurrent or metastatic head and neck squamous cell carcinoma
Antibody, cancer, monoclonal antibody, head and neck squamous cell carcinoma, EGFR/MET inhibitor - Read more

Health Canada authorizes Moderna's mFLUSIVA (mRNA-1010) and mCOFLU (mRNA-1083) mRNA vaccines for influenza and COVID-19 prevention in adults
Vaccine, infectious disease, mRNA vaccine, influenza, COVID-19, combination therapy - Read more

Chai Discovery, Roche partner on AI-driven drug discovery across multiple therapeutic programmes
Research collaboration, AI/ML, drug discovery, protein-based therapeutics, antibody - Read more

Caldera Therapeutics in-licenses second bispecific from Qyuns Therapeutics, expanding inflammatory disease portfolio
Licensing deal, autoimmune, bispecific antibody, IBD, milestone payments - Read more

Eli Lilly, Hims & Hers partner to expand US access to obesity drugs Zepbound and Foundayo
Commercial partnership, obesity, GLP-1, small molecule, digital health, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Merck & Co.'s (efinopegdutide) GLP-1/glucagon receptor co-agonist shows strong Ph2b results in metabolic dysfunction-associated steatohepatitis
Protein therapy, metabolic, GLP-1/glucagon receptor co-agonist, MASH, efinopegdutide, fibrosis - Read more

Anaheim Bio launches with $45M Series A to advance ANA-1 for calcium pyrophosphate deposition disease, targeting underlying crystal buildup
Autoimmune, small molecule, rare disease, preclinical, rheumatology - Read more

Moderna reports 29% revenue growth to $1.3B, driven by global COVID vaccine uptake
mRNA vaccine, infectious disease, revenue impact, competitive - Read more

Nova Anchora raises $23M equity financing to advance topical collagen VII therapy for DEB
Rare disease, protein therapy, dermatology, preclinical - Read more

KyDo Therapeutics secures seed extension financing from existing investors for genetically defined cancer programs
Oncology, small molecule, covalent inhibitor, preclinical, platform technology - Read more

Siemens Healthineers carves out in vitro diagnostics business as standalone Olyrian Diagnostics, rebrands to Healthineers
Carve-out, diagnostics, digital health, laboratory diagnostics - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Merck & Co. drops Sutro Biopharma-partnered IL-2 agonist MK-1484 for solid tumors in pipeline prioritization
Pipeline prioritization, oncology, IL-2, immunotherapy, co-development - Read more

Novo terminates Korro Bio RNA editing collaboration, worth up to $530M, after 12-month pause
Termination, RNA editing, cardiometabolic, milestone payments - Read more

Moderna halts norovirus vaccine cohort enrollment after phase 3 miss, seeks regulatory guidance
mRNA vaccine, infectious disease, strategic, cost reduction - Read more

Novartis confirms 9 tumor cases in Zolgensma patients, raising gene therapy safety concerns
Gene therapy, rare disease, safety, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here